Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGPhase 1INTERVENTIONAL

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.

Who May Be Eligible (Plain English)

Who May Qualify: - Diagnosis of HeFH or premature CAD Who Should NOT Join This Trial: - Homozygous familial hypercholesterolemia - Active or history of chronic liver disease - Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe - Clinically significant or abnormal laboratory values as defined by the protocol Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Diagnosis of HeFH or premature CAD Exclusion Criteria: * Homozygous familial hypercholesterolemia * Active or history of chronic liver disease * Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe * Clinically significant or abnormal laboratory values as defined by the protocol

Treatments Being Tested

DRUG

VERVE-102

Intravenous (IV) infusion

Locations (20)

Clinical Study Center
Dothan, Alabama, United States
Clinical Study Center
Pomona, California, United States
Clinical Study Center
Boca Raton, Florida, United States
Clinical Study Center
Jacksonville, Florida, United States
Clinical Study Center
Winter Park, Florida, United States
Clinical Study Center
High Point, North Carolina, United States
Clinical Study Center
DeSoto, Texas, United States
Clinical Study Center
Renton, Washington, United States
Clinical Study Center
Adelaide, Australia
Clinical Study Center
Melbourne, Australia
Clinical Study Center
Sydney, Australia
Clinical Study Center
Chicoutimi, Canada
Clinical Study Center
Montreal, Canada
Clinical Study Center
Toronto, Canada
Clinical Study Center
Vancouver, Canada
Clinical Study Center
Rehovot, Israel
Clinical Study Center
Christchurch, New Zealand
Clinical Study Center
Birmingham, United Kingdom
Clinical Study Center
Edinburgh, United Kingdom
Clinical Study Center
London, United Kingdom